Abiomed, Inc. ( ABMD) Stock. Should you Buy or Sell? $ 282.28
6.71 (2.32 %)
Abiomed, Inc. Analysis
Updated on 10-09-2022| Symbol | ABMD |
| Price | $282.28 |
| Beta | 1.353 |
| Volume Avg. | $270.81 thousand |
| Market Cap | $12.83 B |
| 52 Week Range | $219.85 - $379.3 |
Abiomed, Inc. opened the day at $282.28 which is +'2.32 % on yesterday's close. Abiomed, Inc. has a 52 week high of $379.3 and 52 week low of $219.85, which is a difference of $159.45. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $12.83 B and total net profit is $1031753000 which means the company is trading at 12.44 times profit to market capitalization. Theoretically, if you were to buy Abiomed, Inc. for $12.83 B, it would take 15 years to get your money back. Abiomed, Inc. are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Abiomed, Inc. Stock Forecast - Is Abiomed, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Buy | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | 59.054 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.206 |
Valuing Abiomed, Inc.
| Price Book Value Ratio | 8.375 | Price To Book Ratio | 8.375 |
| Price To Sales Ratio | 12.179 | Price Earnings Ratio | 59.126 |
How liquid is Abiomed, Inc.
| Current Ratio | 7.533 |
| Quick Ratio | 6.645 |
Debt
| Debt Ratio | 0.098 | Debt Equity Ratio | 0.109 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about Abiomed, Inc.
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.
The company's stock rose steadily throughout the month.
Abiomed, Inc. (NASDAQ:ABMD ) Q1 2023 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair Marie Thibault - BTIG Pito Chickering - Deutsche Bank Chris Pasquale - Nephron Research Matt O'Brien - Piper Sandler Mike Polark - Wolfe Research Jayson Bedford - Raymond James Calvin Chu - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Abiomed FY '23 Q1 Earnings Call.
Abiomed came in with another set of robust earnings yesterday, with double-digit growth from top to bottom. Earnings remain steady, however, the company exhibits the profitability features investors are paying a premium for.
About Abiomed, Inc.
Description :
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
